Otolaryngology, also known as otolaryngology, is a medical discipline dealing with diseases related to the ear, nose, and throat (ENT). Diseases related to the ears, throat and nose can seriously affect the quality of life, and in some cases can lead to surgery such as throat cancer, chronic tonsillitis, severe sinus problems, and ear infections.
In order to treat these diseases, ENT treatment is needed. These diseases can be treated with instruments or drugs; however, surgery is recommended for severely ill patients. According to the recommendations of the otolaryngologist, surgery is required in some cases, such as laryngeal cancer, but the oncologist will perform the tumor resection and then perform radiotherapy or chemotherapy depending on the severity.
Get PDF Brochure with COVID19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-pdf/1326
The global ENT disorder treatment market was valued at USD 9.521.1 billion in 2016 and is expected to reach a compound annual growth rate of 3.22% during the forecast period (2017-2025). One of the main factors leading to the increase in the number of ear, nose and throat diseases is the increase in air and noise pollution, and the increase in the concentration of bacteria in the environment, leading to various infections. According to data from the World Health Organization (WHO), in 2017, approximately 40 percent of the European population was exposed to traffic noise levels exceeding 55 decibels, leading to chronic hearing diseases such as hearing loss and earaches. In addition, air pollution can cause throat infections, as well as sinus infections and other diseases. Several other factors that have contributed to the growth of the ear, nose and throat disease treatment market include high investment in R&D in the development of treatments for ear, nose and throat diseases, especially rhinitis; increase in cases of bacterial and other diseases. However, the side effects and high costs of treatment, together with insufficient understanding of the treatment of ENT diseases, are expected to have a negative impact on the growth of the market.
New antibiotic development and increased approvals for antibiotics will provide opportunities for market growth in anticipated years. In April 2014, the FDA approved Grastek for the treatment of allergic rhinitis caused by pollen developed by Merck.
North America is projected to dominate the global ENT disorder treatment market during the forecast period. This is due to the large presence of major players and the growing interest in improving existing treatment options. In December 2017, an American company Intersect ENT, Inc. received FDA approval of Sinuva (mometasone furoate) breast implants as a treatment option for patients with recurrent nasal polyps.
The Asia Pacific region is expected to experience significant growth due to increased awareness of the availability of drug treatments for ENT diseases and expansion of major suppliers in Asian countries through the establishment of new facilities, manufacturing and distribution. In October 2017, a major pharmaceutical company GlaxoSmithKline opened its Asian headquarters in OneNorth, Singapore.
The development of new therapies and product launches are drivers of the global ENT disorder treatment market growth. Recently, due to continuous research and development, the U.S. Food and Drug Administration (FDA) has approved many products for ENT diseases to provide effective and effective treatment options. In December 2015, the U.S.-based company, Otonomy, Inc. obtained FDA approval to market its new antibiotic OTIPRIO (Cycloprosin Ear Suspension) for the treatment of pediatric patients with bilateral otitis media.
Major players also focus on inorganic strategies, such as mergers and acquisitions, to improve the commercialization of research departments and products in sales and marketing.
Major companies contributing in the global ENT disorder treatment market Siemens Healthcare, William Demant Holding A/S, Cochlear Ltd., Allergan plc, Dr. Reddys Laboratories Ltd., Panasonic Corp., Rexton Inc., Otonomy Inc., GlaxoSmithKline Pharmaceuticals, Mylan N.V., Teva Pharmaceutical Industries Ltd., Nuear Hearing Aids Inc., MED-EL GmbH, Merck & Co., Miracle-Ear Inc., Avada Hearing Care, Beltone, Sonic Innovations Inc., GN ReSound A/S, Sonova Holding AG, Widex A/S, and Starkey Laboratories Inc.
Purchase This Premium Report Here With Discounted Price (Flat US $2000 Off) – https://www.coherentmarketinsights.com/promo/buynow/1326
Reasons to Purchase this Report
• Current and future of global ENT Disorder Treatment market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027